| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for Avantogen Ltd. > News item |
Avantogen, Innovate say RP101 'significantly' delays time to progression in pancreatic cancer
By Elaine Rigoli
Tampa, Fla., June 8 - Avantogen Ltd. and Innovate Oncology, Inc. reported the findings of a phase 1 pilot trial of 13 patients with advanced pancreatic cancer, which assessed the efficacy of RP101 in combination with gemcitabine and cisplatin, versus an appropriate historical control, consisting of patients who received the combination of gemcitabine and cisplatin only.
In this study, all patients showed at least stable disease, and 33% of patients showed a partial remission.
In the RP101 co-treatment group, the median survival was significantly longer than that seen in the historical control group (447 days versus 186 days) and time to progression was also prolonged (280 days versus 104 days).
Ten of the 13 patients lived longer than one year and four remained alive nearly two years after the first treatment, according to a news release.
The company also reported the interim findings of an ongoing dose-ranging study in which 22 patients with advanced pancreatic cancer received varying doses of RP101 in addition to fixed-dose gemcitabine.
At the time of this interim analysis, 36% of patients had been followed for less than six months and pooled data of those patients followed for six months or more showed 41% of patients were still alive and 23% had died.
The median survival at this stage of follow up is 7.1 months and 14/22 patients (64%) were still alive, the release said.
Avantogen, located in Sydney, Australia, is an international biotechnology company developing a broad oncology-related product portfolio.
Innovate is an international biotechnology company located in New York.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.